;PMID: 3437890
;source_file_2867.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..39] = [t:0..39]
;1)sentence:[e:45..97] = [t:45..97]
;2)section:[e:101..123] = [t:101..123]
;3)section:[e:127..232] = [t:127..232]
;4)sentence:[e:236..360] = [t:236..360]
;5)sentence:[e:361..431] = [t:361..431]
;6)sentence:[e:432..549] = [t:432..549]
;7)sentence:[e:550..796] = [t:550..796]
;8)sentence:[e:797..944] = [t:797..944]
;9)sentence:[e:945..1008] = [t:945..1008]
;10)sentence:[e:1009..1090] = [t:1009..1090]
;11)sentence:[e:1092..1218] = [t:1092..1218]
;12)sentence:[e:1219..1332] = [t:1219..1332]
;13)section:[e:1336..1380] = [t:1336..1380]

;section 0 Span:0..39
;Mol Cell Biol.  1987 Dec;7(12):4266-72.
(SEC
  (FRAG (NNP:[0..3] Mol) (NNP:[4..8] Cell) (NNP:[9..13] Biol) (.:[13..14] .)
        (CD:[16..20] 1987) (NNP:[21..25] Dec;) (HYPH:[25..27] 7-LRB-)
        (CD:[27..29] 12) (-RRB-:[29..30] -RRB-) (::[30..31] :)
        (CD:[31..38] 4266-72) (.:[38..39] .)))

;sentence 1 Span:45..97
;Alternative processing of RNA transcribed from NMYC.
;[92..96]:gene-rna:"NMYC"
(SENT
  (NP-HLN
    (NP (JJ:[45..56] Alternative) (NN:[57..67] processing))
    (PP (IN:[68..70] of)
      (NP
        (NP (NN:[71..74] RNA))
        (VP (VBN:[75..86] transcribed)
          (NP (-NONE-:[86..86] *))
          (PP (IN:[87..91] from)
            (NP (NN:[92..96] NMYC))))))
    (.:[96..97] .)))

;section 2 Span:101..123
;Stanton LW, Bishop JM.
(SEC
  (FRAG (NNP:[101..108] Stanton) (NNP:[109..111] LW) (,:[111..112] ,)
        (NNP:[113..119] Bishop) (NNP:[120..122] JM) (.:[122..123] .)))

;section 3 Span:127..232
;Department of Microbiology and Immunology, University of California Medical 
;Center, San Francisco 94143.
(SEC
  (FRAG (NNP:[127..137] Department) (IN:[138..140] of)
        (NNP:[141..153] Microbiology) (CC:[154..157] and)
        (NNP:[158..168] Immunology) (,:[168..169] ,) (NNP:[170..180] University)
        (IN:[181..183] of) (NNP:[184..194] California) (NNP:[195..202] Medical)
        (NNP:[204..210] Center) (,:[210..211] ,) (NNP:[212..215] San)
        (NNP:[216..225] Francisco) (CD:[226..231] 94143) (.:[231..232] .)))

;sentence 4 Span:236..360
;NMYC is a gene whose amplification and overexpression have been implicated in
; the generation of certain human malignancies.
;[236..240]:gene-rna:"NMYC"
;[257..270]:variation-type:"amplification"
(SENT
  (S
    (NP-SBJ (NN:[236..240] NMYC))
    (VP (VBZ:[241..243] is)
      (NP-PRD
        (NP (DT:[244..245] a) (NN:[246..250] gene))
        (SBAR
          (WHNP-1
            (NP (WP$:[251..256] whose))
            (NN:[257..270] amplification) (CC:[271..274] and)
             (NN:[275..289] overexpression))
          (S
            (NP-SBJ-1 (-NONE-:[289..289] *T*))
            (VP (VBP:[290..294] have)
              (VP (VBN:[295..299] been)
                (VP (VBN:[300..310] implicated)
                  (NP-1 (-NONE-:[310..310] *))
                  (PP (IN:[311..313] in)
                    (NP
                      (NP (DT:[315..318] the) (NN:[319..329] generation))
                      (PP (IN:[330..332] of)
                        (NP (JJ:[333..340] certain) (JJ:[341..346] human)
                            (NNS:[347..359] malignancies))))))))))))
    (.:[359..360] .)))

;sentence 5 Span:361..431
;Little is known of how the  expression of NMYC is normally controlled.
;[403..407]:gene-rna:"NMYC"
(SENT
  (S
    (NP-SBJ-1 (JJ:[361..367] Little))
    (VP (VBZ:[368..370] is)
      (VP (VBN:[371..376] known)
        (NP-1 (-NONE-:[376..376] *))
        (PP (IN:[377..379] of)
          (SBAR-NOM
            (WHADVP-3 (WRB:[380..383] how))
            (S
              (NP-SBJ-2
                (NP (DT:[384..387] the) (NN:[389..399] expression))
                (PP (IN:[400..402] of)
                  (NP (NN:[403..407] NMYC))))
              (VP (VBZ:[408..410] is)
                (ADVP (RB:[411..419] normally))
                (VP (VBN:[420..430] controlled)
                  (NP-2 (-NONE-:[430..430] *))
                  (ADVP-3 (-NONE-:[430..430] *T*)))))))))
    (.:[430..431] .)))

;sentence 6 Span:432..549
;We have therefore characterized  transcription from the gene and the
;structure and stability of the resulting  mRNAs.
(SENT
  (S
    (NP-SBJ (PRP:[432..434] We))
    (VP (VBP:[435..439] have)
      (ADVP (RB:[440..449] therefore))
      (VP (VBN:[450..463] characterized)
        (NP
          (NP (NN:[465..478] transcription))
          (PP (IN:[479..483] from)
            (NP
              (NP (DT:[484..487] the) (NN:[488..492] gene))
              (CC:[493..496] and)
              (NP
                (NP (DT:[497..500] the) (NN:[501..510] structure)
                    (CC:[511..514] and) (NN:[515..524] stability))
                (PP (IN:[525..527] of)
                  (NP (DT:[528..531] the) (VBG:[532..541] resulting)
                      (NNS:[543..548] mRNAs)))))))))
    (.:[548..549] .)))

;sentence 7 Span:550..796
;Transcription from NMYC is exceptionally complex: it initiates at  numerous
;sites that may be grouped under the control of two promoters, and the 
;multiplicity of initiation sites combines with alternative splicing to
;engender  two forms of mRNA.
;[569..573]:gene-rna:"NMYC"
(SENT
  (S
    (S
      (NP-SBJ
        (NP (NN:[550..563] Transcription))
        (PP (IN:[564..568] from)
          (NP (NN:[569..573] NMYC))))
      (VP (VBZ:[574..576] is)
        (ADJP-PRD (RB:[577..590] exceptionally) (JJ:[591..598] complex)
                  (::[598..599] :)
          (S
            (NP-SBJ (PRP:[600..602] it))
            (VP (VBZ:[603..612] initiates)
              (PP-LOC (IN:[613..615] at)
                (NP
                  (NP (JJ:[617..625] numerous) (NNS:[626..631] sites))
                  (SBAR
                    (WHNP-1 (WDT:[632..636] that))
                    (S
                      (NP-SBJ-1 (-NONE-:[636..636] *T*))
                      (VP (MD:[637..640] may)
                        (VP (VB:[641..643] be)
                          (VP (VBN:[644..651] grouped)
                            (NP-1 (-NONE-:[651..651] *))
                            (PP (IN:[652..657] under)
                              (NP
                                (NP (DT:[658..661] the) (NN:[662..669] control))
                                (PP (IN:[670..672] of)
                                  (NP (CD:[673..676] two)
                                      (NNS:[677..686] promoters)))))))))))))))))
    (,:[686..687] ,) (CC:[688..691] and)
    (S
      (NP-SBJ
        (NP (DT:[692..695] the) (NN:[697..709] multiplicity))
        (PP (IN:[710..712] of)
          (NP (NN:[713..723] initiation) (NNS:[724..729] sites))))
      (VP (VBZ:[730..738] combines)
        (PP (IN:[739..743] with)
          (NP (JJ:[744..755] alternative) (NN:[756..764] splicing)))
        (S
          (NP-SBJ (-NONE-:[764..764] *))
          (VP (TO:[765..767] to)
            (VP (VB:[768..776] engender)
              (NP
                (NP (CD:[778..781] two) (NNS:[782..787] forms))
                (PP (IN:[788..790] of)
                  (NP (NN:[791..795] mRNA)))))))))
    (.:[795..796] .)))

;sentence 8 Span:797..944
;The mRNAs have different 5' leader sequences (alternative  first exons of the
;gene) but identical bodies (the second and third exons of the  gene).
(SENT
  (S
    (NP-SBJ (DT:[797..800] The) (NNS:[801..806] mRNAs))
    (VP (VBP:[807..811] have)
      (NP
        (NP (JJ:[812..821] different)
          (NML (CD:[822..823] 5) (SYM:[823..824] '))
          (NN:[825..831] leader) (NNS:[832..841] sequences)
          (PRN (-LRB-:[842..843] -LRB-)
            (NP
              (NP (JJ:[843..854] alternative) (JJ:[856..861] first)
                  (NNS:[862..867] exons))
              (PP (IN:[868..870] of)
                (NP (DT:[871..874] the) (NN:[875..879] gene))))
            (-RRB-:[879..880] -RRB-)))
        (CC:[881..884] but)
        (NP (JJ:[885..894] identical) (NNS:[895..901] bodies)
          (PRN (-LRB-:[902..903] -LRB-)
            (NP
              (NP (DT:[903..906] the)
                (ADJP (JJ:[907..913] second) (CC:[914..917] and)
                      (JJ:[918..923] third))
                (NNS:[924..929] exons))
              (PP (IN:[930..932] of)
                (NP (DT:[933..936] the) (NN:[938..942] gene))))
            (-RRB-:[942..943] -RRB-)))))
    (.:[943..944] .)))

;sentence 9 Span:945..1008
;Both forms of mRNA are unstable, with half-lives of ca. 15 min.
(SENT
  (S
    (NP-SBJ
      (NP (DT:[945..949] Both) (NNS:[950..955] forms))
      (PP (IN:[956..958] of)
        (NP (NN:[959..963] mRNA))))
    (VP (VBP:[964..967] are)
      (ADJP-PRD (JJ:[968..976] unstable))
      (,:[976..977] ,)
      (PP (IN:[978..982] with)
        (NP
          (NP
            (NML (JJ:[983..987] half) (HYPH:[987..988] -))
            (NNS:[988..993] lives))
          (PP (IN:[994..996] of)
            (NP
              (ADVP (RB:[997..1000] ca.))
              (CD:[1001..1003] 15) (NN:[1004..1007] min))))))
    (.:[1007..1008] .)))

;sentence 10 Span:1009..1090
;Both  encode the previously identified 65,000 and 67,000-dalton products of
;NMYC.
;[1085..1089]:gene-rna:"NMYC"
(SENT
  (S
    (NP-SBJ (DT:[1009..1013] Both))
    (VP (VBP:[1015..1021] encode)
      (NP
        (NP (DT:[1022..1025] the)
          (ADJP (RB:[1026..1036] previously) (VBN:[1037..1047] identified)
            (NML
              (NML (CD:[1048..1054] 65,000)
                (NML-1 (-NONE-:[1054..1054] *P*)))
              (CC:[1055..1058] and)
              (NML (CD:[1059..1065] 67,000) (HYPH:[1065..1066] -)
                (NML-1 (NN:[1066..1072] dalton) (NNS:[1073..1081] products))))))
        (PP (IN:[1082..1084] of)
          (NP (NN:[1085..1089] NMYC)))))
    (.:[1089..1090] .)))

;sentence 11 Span:1092..1218
;However, the alternative first exons contain distinctive open reading frames 
;that may diversify the coding potential of NMYC.
;[1213..1217]:gene-rna:"NMYC"
(SENT
  (S
    (ADVP (RB:[1092..1099] However))
    (,:[1099..1100] ,)
    (NP-SBJ (DT:[1101..1104] the) (JJ:[1105..1116] alternative)
            (JJ:[1117..1122] first) (NNS:[1123..1128] exons))
    (VP (VBP:[1129..1136] contain)
      (NP
        (NP (JJ:[1137..1148] distinctive) (JJ:[1149..1153] open)
            (NN:[1154..1161] reading) (NNS:[1162..1168] frames))
        (SBAR
          (WHNP-1 (WDT:[1170..1174] that))
          (S
            (NP-SBJ-1 (-NONE-:[1174..1174] *T*))
            (VP (MD:[1175..1178] may)
              (VP (VB:[1179..1188] diversify)
                (NP
                  (NP (DT:[1189..1192] the) (NN:[1193..1199] coding)
                      (NN:[1200..1209] potential))
                  (PP (IN:[1210..1212] of)
                    (NP (NN:[1213..1217] NMYC))))))))))
    (.:[1217..1218] .)))

;sentence 12 Span:1219..1332
;The complexities in  transcription of NMYC expand the means by which
;expression of the gene might be  controlled.
;[1257..1261]:gene-rna:"NMYC"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1219..1222] The) (NNS:[1223..1235] complexities))
      (PP (IN:[1236..1238] in)
        (NP
          (NP (NN:[1240..1253] transcription))
          (PP (IN:[1254..1256] of)
            (NP (NN:[1257..1261] NMYC))))))
    (VP (VBP:[1262..1268] expand)
      (NP
        (NP (DT:[1269..1272] the) (NNS:[1273..1278] means))
        (SBAR
          (WHPP-2 (IN:[1279..1281] by)
            (WHNP (WDT:[1282..1287] which)))
          (S
            (NP-SBJ-1
              (NP (NN:[1288..1298] expression))
              (PP (IN:[1299..1301] of)
                (NP (DT:[1302..1305] the) (NN:[1306..1310] gene))))
            (VP (MD:[1311..1316] might)
              (VP (VB:[1317..1319] be)
                (VP (VBN:[1321..1331] controlled)
                  (NP-1 (-NONE-:[1331..1331] *))
                  (PP-2 (-NONE-:[1331..1331] *T*)))))))))
    (.:[1331..1332] .)))

;section 13 Span:1336..1380
;PMID: 3437890 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1336..1340] PMID) (::[1340..1341] :) (CD:[1342..1349] 3437890)
        (NN:[1350..1351] -LSB-) (NNP:[1351..1357] PubMed) (::[1358..1359] -)
        (NN:[1360..1367] indexed) (IN:[1368..1371] for)
        (NNP:[1372..1380] MEDLINE-RSB-)))
